Literature DB >> 1095689

Metoclopramide and pimozide in Parkinson's disease and levodopa-induced dyskinesias.

D Tarsy, J D Parkes, C D Marsden.   

Abstract

Metoclopramide is an antiemetic drug which occasionally produced acute dystonic reactions. Although known to interfere with central dopamine mechanisms, it is frequently used in Parkinson's disease to prevent levodopa-induced nausea and vomiting. In this study metoclopramide did not increase Parkinsonism or reduce levodopa-induced involuntary movements in patients with Parkinson's disease. Pimozide, by contrast, increased Parkinsonism and reduced involuntary movements. The capacity of metoclopramide to produce acute dyskinesias while being apparently free of Parkinsonism effects is pharmacologically unique and differentiates this drug from the phenothiazines and butyrophenones.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1095689      PMCID: PMC491929          DOI: 10.1136/jnnp.38.4.331

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  20 in total

1.  [PROTECTION EXERCISED BY METOCLOPRAMIDE AGAINST THE VOMITIVE EFFECTS OF COPPER SULFATE].

Authors:  C LAVILLE
Journal:  Pathol Biol       Date:  1964-05

2.  [ANTIEMETIC ACTION OF METOCLOPRAMIDE WITH RESPECT TO APOMORPHINE AND HYDERGINE].

Authors:  L JUSTIN-BESANCON; C LAVILLE
Journal:  C R Seances Soc Biol Fil       Date:  1964

3.  [TECHNIC FOR THE STUDY OF THE CENTRAL ACTION OF EMETIC AND ANTIEMETIC POISONS].

Authors:  J MALMEJAC; C LAVILLE; J MARGARIT
Journal:  C R Seances Soc Biol Fil       Date:  1964

4.  Prolactin secretion in patients treated with various drugs: phenothiazines, tricyclic antidepressants, reserpine, and methyldopa.

Authors:  R W Turkington
Journal:  Arch Intern Med       Date:  1972-09

Review 5.  Dopamine in the basal ganglia. Its role and therapeutic implications (including the clinical use of L-DOPA).

Authors:  O Hornykiewicz
Journal:  Br Med Bull       Date:  1973-05       Impact factor: 4.291

Review 6.  Antipsychotic drug actions: a clue to the neuropathology of schizophrenia?

Authors:  S Matthysse
Journal:  Fed Proc       Date:  1973-02

7.  Letter: Fenfluramine and dyskinesias.

Authors:  I Shoulson; T N Chase
Journal:  N Engl J Med       Date:  1974-10-17       Impact factor: 91.245

8.  A year's comparison of treatment of patients with parkinson's disease with levodopa combined with carbidopa versus treatment with levodopa alone.

Authors:  C D Marsden; J D Parkes; J E Rees
Journal:  Lancet       Date:  1973-12-29       Impact factor: 79.321

9.  Receptor activity and turnover of dopamine and noradrenaline after neuroleptics.

Authors:  N E Andén; S G Butcher; H Corrodi; K Fuxe; U Ungerstedt
Journal:  Eur J Pharmacol       Date:  1970       Impact factor: 4.432

10.  Attempted use of haloperidol in the treatment of L-dopa induced dyskinesias.

Authors:  H L Klawans; W J Weiner
Journal:  J Neurol Neurosurg Psychiatry       Date:  1974-04       Impact factor: 10.154

View more
  17 in total

1.  Buspirone in the treatment of levodopa induced dyskinesias.

Authors:  B Kleedorfer; A J Lees; G M Stern
Journal:  J Neurol Neurosurg Psychiatry       Date:  1991-04       Impact factor: 10.154

Review 2.  Pharmacological Agents Affecting Emesis : A Review (Part II).

Authors:  F Mitchelson
Journal:  Drugs       Date:  1992-04       Impact factor: 9.546

3.  Bromocriptine and dopamine receptor stimulation.

Authors:  A G Debono; C D Marsden; P Asselman; J D Parkes
Journal:  Br J Clin Pharmacol       Date:  1976-12       Impact factor: 4.335

4.  Metoclopramide and tardive dyskinesia in the elderly.

Authors:  M L Orme; R C Tallis
Journal:  Br Med J (Clin Res Ed)       Date:  1984-08-18

Review 5.  Assessment of extrapyramidal disorders.

Authors:  C D Marsden; M Schachter
Journal:  Br J Clin Pharmacol       Date:  1981-02       Impact factor: 4.335

6.  Tiapride in levodopa-induced involuntary movements.

Authors:  A J Lees; C M Lander; G M Stern
Journal:  J Neurol Neurosurg Psychiatry       Date:  1979-04       Impact factor: 10.154

7.  Oxiperomide in tardive dyskinesia.

Authors:  D E Casey; J Gerlach
Journal:  J Neurol Neurosurg Psychiatry       Date:  1980-03       Impact factor: 10.154

Review 8.  Pimozide: a review of its pharmacological properties and therapeutic uses in psychiatry.

Authors:  R M Pinder; R N Brogden; R Swayer; T M Speight; R Spencer; G S Avery
Journal:  Drugs       Date:  1976       Impact factor: 9.546

Review 9.  Metoclopramide: a review of its pharmacological properties and clinical use.

Authors:  R M Pinder; R N Brogden; P R Sawyer; T M Speight; G S Avery
Journal:  Drugs       Date:  1976       Impact factor: 9.546

10.  The synaptic significance of metoclopramide induced dyskinetic-dystonic head and neck movements in pregnancy.

Authors:  J J Askenasy; M Streifler; S Felner
Journal:  J Neural Transm       Date:  1978       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.